Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for 250mg crizotinib

Release date: 2024-07-10 11:21:25     Recommended: 198

04L0967_23 克唑替尼 批文_00.jpg

Crizotinib is suitable for the treatment of locally advanced or metastatic NSCLC with ALK positivity, as well as NSCLC diseases with ROS1 positivity. It is a tyrosine kinase inhibitor (TKI) that plays a therapeutic role in treating patients with advanced non-small cell lesions that are ALK positive and certain MET amplifications. Clozotinib inhibits the activity of certain specific tyrosine kinases, blocks cellular signaling pathways, and inhibits the growth and spread of diseased cells.

Company News

Research News

Drug news